SETD7 and cancer: As expected, RORα2 WT increased mRNA levels of CTNND1, whereas RORα2 K87R resulted in decreased levels of CTNND1. These results indicate that RORα2 confers a transcriptional activator function on target gene promoters, which are related to cancer progression by the enhanced binding to coactivator complex via SETD7-dependent methylation on lysine 87 of RORα2 (Figure 4D).